三生制药今日盘中股价出现大幅下跌，跌幅达6.46%，市场表现引人关注。
消息面上，国信证券发布报告指出，三生制药的国内药品销售业务存在一定压力。基于此，该机构小幅下调了公司2026-2027年的盈利预测，并新增了2028年的预测。具体来看，预计2026年至2028年公司归母净利润分别为24.5亿元、26.6亿元和27.9亿元，其中2026年预测较此前值28.8亿元有所下调。这一盈利预期的下调，被认为是导致股价承压下行的重要原因。
报告同时也提到，公司的在研药物“707”快速开启了全球3期多中心临床，未来有望成为重磅产品，并因此维持了对公司“优于大市”的评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.